DocetaxelA Pharmacoeconomic Review of its Use in the Treatment of Metastatic Breast Cancer

被引：0
作者：
Harriet M. Lamb
Lynda R. Wiseman
机构：
[1] Adis International Limited,
来源：
PharmacoEconomics | 1998年 / 14卷
关键词：
Breast Cancer; Paclitaxel; Docetaxel; Adis International Limited; Metastatic Breast Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Advanced breast cancer has a poor prognosis (median duration of survival about 2 years); thus, treatment options are largely palliative. Recent studies with the taxoids docetaxel and paclitaxel suggest that these agents are effective second- line therapy in patients with metastatic breast cancer. Objective response rates range from 30 to 57% with docetaxel monotherapy in clinical trials in patients with advanced disease who had failed to respond to previous therapy, and the median time to disease progression ranges from 17 to 20 weeks.
引用
收藏
页码：447 / 459
页数：12
相关论文
共 100 条
[1]  
Rubens RD(1996)Key issues in the treatment of advanced breastcancer: expectations and outcomes Pharmacoeconomics 2 1-7
[2]  
Boring CC(1994)Cancer statistics 1994 CA Cancer J Clin 44 7-26
[3]  
Squires TS(1996)Long-termfollow-up of patients with complete remission followingcombination chemotherapy of metastatic breast cancer J Clin Oncol 14 2197-205
[4]  
Tong T(1992)Progress in chemotherapy formetastatic breast cancer Semin Oncol 19 317-32
[5]  
Greenberg PAC(1997)Anthracycline resistance: the problem and its currentdefinition Semin Oncol 10 S10-11-S10-17
[6]  
Hortobagyi GN(1998)The taxoids: comparative clinicalpharmacology and therapeutic potential Drugs 55 5-30
[7]  
Smith TL(1996)Docetaxel: a review of its pharmacodynamicand pharmacokinetic properties and therapeutic efficacyin the management of metastatic breast cancer Drugs 51 1075-92
[8]  
Sledge GW(1994)Paclitaxel: a review of its pharmacodynamicand pharmacokinetic properties and therapeutic potentialin the treatment of cancer Drugs 48 794-847
[9]  
Antman KM(1997)Docetaxel vs doxorubicin in metastatic breast cancerresistant to alkylating chemotherapy Oncology (Huntingt) 8 19-24
[10]  
Gianni L(1993)Advanced breastcancer: use of resources and cost implications Br J Cancer 67 856-60
12345678910